Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Sep 30, 2024
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The sequential growth was moderate, while the year-over-year gain was more pronounced.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The sequential growth was moderate, while the year-over-year gain was more pronounced.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$3.7B
Revenue reported for this quarter.
Quarter-over-quarter
+4.9%
Change from the immediately preceding quarter.
Year-over-year
+10.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$13.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $3.4B | +0.6% |
| Mar 31, 2024 | $3.1B | -0.5% |
| Jun 30, 2024 | $3.5B | +12.3% |
| Sep 30, 2024 | $3.7B | +10.6% |
Revenue performance
The reported revenue rose from the immediately preceding quarter, continuing an upward trajectory. This marks the highest quarterly revenue in the trailing twelve-month period shown.
Quarterly comparison
Compared with the same quarter one year earlier, revenue was higher, reflecting a stronger year-over-year performance. The sequential increase from the prior quarter was smaller in magnitude than the annual gain.
What to watch
The filing context does not provide specific commentary on revenue drivers for this quarter.